RPI-1

RPI-1 is an ATP-dependent RET kinase inhibitor. It has been shown to selectively inhibit the anchorage-independent growth of NIH3T3 cells transformed by the ret/ptc1 oncogene with an IC50 value of 0.97 µM. In a spontaneously metastasizing lung carcinoma xenograft mouse model, daily oral treatment with RPI-1 was reported to significantly reduce spontaneous lung metastases.Formal Name: 1,3-dihydro-3-[(4-hydroxyphenyl)methylene]-5,6-dimethoxy-2H-indol-2-one. CAS Number: 269730-03-2. Molecular Formula: C17H15NO4. Formula Weight: 297.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 15 mg/ml, DMF:PBS (pH 7.2) (1:6): 0.14 mg/ml, DMSO: 10 mg/ml, Ethanol: 1 mg/ml. lambdamax: 272, 346, 413 nm. SMILES: COC1=C(OC)C=C(/C(C(N2)=O)=C/C3=CC=C(O)C=C3)C2=C1. InChi Code: InChI=1S/C17H15NO4/c1-21-15-8-12-13(7-10-3-5-11(19)6-4-10)17(20)18-14(12)9-16(15)22-2/h3-9,19H,1-2H3,(H,18,20)/b13-7-. InChi Key: JGSMCYNBVCGIHC-QPEQYQDCSA-N.